Vigabatrin (gamma-vinyI-GABA or GVG) is an irreversible inhibitor of gamma-aminobutyric acid transaminase (GABA-T), which is an enzyme responsible for gamma-aminobutyric acid (GABA) catabolism. Inhibition of GABA catabolism increases brain concentration of GABA, a neural inhibitor. GVG has been found to be a potent new anti-epileptic drug, especially in the treatment of refractory epilepsy, in particular of complex partial seizures. Three patients who developed a severe status epilepitcus while on GVG treatment are reported.
INTRODUCTION
Vigabatrin (gamma-vinyl-GABA or GVG) is the first rationally-developed drug against epileptic seizures available I. GVG is a selective, enzymeactivated, irreversible inhibitor of GABAtransaminase, the enzyme which is primarily responsible for the catabolism of gammaaminobutyric acid (GABA) 2. The inhibition of GABA catabolism by GVG increases brain concentration of GABA, an important inhibiting neurotransmitter. Several studies suggest that an increase of brain GABA protects against seizures 3.
GVG is indicated in the treatment of refractory epilepsy and in particular of refractory complex partial seizures in adults and children and of infantile spasms/atonic myoclonic attacks in children 4. Adverse effects are hyperkinesia especially in mentally retarded children, somnolence and weight increase.
Most adverse effects are seen in the early treatment phase while chronic treatment adverse reactions are uncommon 5.
CASE REPORTS
We report on three cases with a status epilepticus (SE) during GVG therapy. The first patient is a 17-year-old female, whose pregnancy and birth were uneventful. At the age of 15 months she was said to have had a 'flu', after which a regression of her motor and intellectual skills was noticed. At the age of 5, she suffered from a viral meningitis. At that time a spastic tetraparesis, symptomatic generalized epilepsy with generalized continuous clonic movements, periods of impaired consciousness and a moderate mental handicap were seen. Her medical treatment was sodiumvalporate (VPA) 900 rag/day and clonazepam (CZP) 0.5 rag/day.
At the age of 12, after several nights with partial sleep deprivation, she had a tonic-clonic SE during a disco party (for which she had to be admitted to a hospital), which was stopped by CZP intravenously. After being discharged, her medical treatment was continued unchanged. At the age of 17, she developed a partial epileptic seizure, involving jerking of the right arm and jerky eye movements. As a result of secondary generalization of this seizure she had to be hospitalized. Administration of diazepam (20 mg by rectiole), CZP (Tmg iv.) and phenytoin (DPH) (iv. loading dose 600mg and a maintenance dose of 200 rag/day, bloodlevel 14 mg/l) showed no effect, so a thiopentone coma with burst suppression activity on the EEG was induced. CT-scan of the brain and examination of cerebrospinal fluid were normal. After 1 day thiopentone tapering was begun over a period of 5 days. Her medication was then DPH (200mg/24 hours, later reduced to 75mg/24 hours) and, if necessary, CZP. Phenobarbitone (PB 200mg/day) was added because of continuous clonic movements with corresponding spike wave complexes in the EEG. After this, treatment with GVG (2z500mg/day, later 2 × 1 000mg/day), was started and DPH was stopped at the same time. During the next 19 days she improved and was better than ever before, the clonic movements almost disappearing. PB was tapered with 25 mg because of drowsiness. Then she had a partial seizure which evolved to a generalized convulsive SE. Neither CZP (6mg intravenously), nor diazepam (10mg intravenously) nor sodiumvalproate (1 200mg intravenously) were successful. Again a thiopentone coma (with a suppression-burst pattern on the EEG) had to be induced. Flunarizine (10 mg/day) was added to the medication because of persisting myoclonic activity. GVG was tapered over 5 days. Thiopentone (100-200 mg/hour) was administered over a period of 15 days and tapered over 6 days. PB was increased (to 300 mg/day) and CZP was administered at a maintenance dose of 3 mg/day. She regained consciousness slowly but still showed some clonic movements. At that time, she was worse than before admission, unable to communicate verbally and wheelchair bound. She was transferred to a daycare rehabilitation centre.
Screening of blood and a 24 hour sample of urine for abnormal metabolites was negative. EMG and nerve conduction tests revealed axonal polyneuropathy. Her condidion worsened and without warning she died, supposedly due to pneumonia. Autopsy was not allowed and a definite diagnosis could not be made. So, a tentative diagnosis of neuro-axonal dystrophy was made.
The second case concerns a woman with M. Von Recklinghausen. At the age of 16 she had a left fronto-parietal fibro-sarcoma removed and subsequent radiotherapy. Soon afterwards she had a simple partial seizure (with clonic movements of her right hand and right corner of the mouth). Treatment with DPH (450 mg/day) and carbamazepine (CBZ) (600 mg/day) was successful. At the age of 24, seizures reappeared, DPH was replaced by GVG (1 500mg/day) an the CBZ dose was raised to 800mg/day. A few months later she had a seizure with a post-ictal right-sided paresis of arm and face. During this seizure she remained conscious. The EEG showed focal epileptic activity in the left frontal and anterior temporal leads with postictal slowing over almost the entire left hemisphere. During the next month, she repeatedly had simple partial seizures which could be stopped by CZP. The CBZ bloodlevel was 8.5 mg/l at that time.
Seven weeks later she was readmitted due to a simple-partial SE alternated by a complex-partial SE of several hours duration, due to which she became drowsy and was unable to take her AED. SE was cut by CZP (8 mg/day). On admission CBZ bloodlevel was not assessed. She was loaded with 1 100mg DPH intravenously (bloodlevel 10mg/l) and transferred to the intensive care unit. The next day her CBZ bloodlevel was 7.5 mg/l on a dose of 800 mg/day. This partial SE recurred daily during 10 days in spite of DPH levels ranging from 10 to 20 mg/l and CBZ levels of 6.5 to 9.5 mg/l. Five days after admission GVG was stopped. At that time she was on CBZ (1 200 rag/day, bloodlevel 6.5 mg/l), CZP (8mg/day) and DPH (400mg/day, bloodlevel 10 mg/I). She had no further seizures four days after stopping GVG and was discharged in a good clinical condition. However she continued to have low frequent seizures (simple partial alternated by complex partial fits) on DPH 300 mg (bloodlevel 13mg/1) and controlled release CBZ 1 200 mg (bloodlevel 8 mg/1) and CZP 2 mg.
The third case concerns a 33-year-old, mentally handicapped (IQ 40), female patient, who had symptomatic generalized epilepsy with tonicclonic and complex partial seizures from the age of four years. She had never before had a SE. While on oxcarbazepine (OCB) 1 500mg/day and clobazam 20mg/day, the frequency of the (mainly complex partial) seizures was on average 0.5-1.0 per 24 hours. GVG was started with 1 000mg/day and raised in 2 weeks to 2000 mg/day. At the same time OCB was tapered with 1 tablet/week for 5 weeks. Sixteen days after the institution of GVG, while on 2 000 mg GVG and 300 mg OCB, she developed serial tonic-clonic seizures, which eventually evolved to a 13 hour-long generalized convulsive SE, despite rectally administered diazepam (8 x 10 mg.) and CZP (2 x 2 mg intravenously). On admission she still had a generalized convulsive SE. Midazolam (15 mg intramuscularly), CZP (4 mg intravenous loading dose and 1 mg/hr continuous intravenous infusion) and DPH (1 100 mg intravenous loading dose, bloodlevel 20mg/l) were found to be unsuccessful in the hours after admission. So, after intubation, propofol was started (50mg intravenous loading dose in three minutes, 6mg/hour continous intravenous infusion) and the SE ceased. Mechanical ventilation was not necessary. Because no other cause or precipitating factor for the status could be found, GVG was discontinued.
DISCUSSION
Exacerbation of seizures due to anti-epileptic drugs (AED), though adequate for the specific seizure type has been described only occasionally. Toxic serum levels of DPH may increase seizure frequency or even precipitate SE% Administration of benzodiazepines may result in an aggravation of tonic seizures in symptomatic generalized epilepsy v's. CBZ has been reported to induce absences, myoclonic, tonic and generalized seizures as well as absence status '~")'j~. On the whole, a frank deterioration like SE due to commonly used anti-epileptic drugs is very unusual.
Recently four cases of complex partial SE with a duration of 5-14 days have been described in patients on GVG t2` as well as stupor and myoclonic jerks in a patient during GVG treatment, which disappeared after discontinuation of GVG 13.
Another (retrospective) study on 57 patients on GVG as comedication reports five patients who developed SE after 2-8 months of GVG treatment. Two of them had their original AED reduced or stopped (but were seizure free two and eight months on this regime), a third patient with cerebral metastasis had SE two days before he died due to cerebral herniation. In the remaining two patients no clear cause would be detected za.
The three patients described in our case report also developed SE during GVG treatment. Remarkably, the SE only disappeared after GVG was discontinued. To explain these phenomena we hypothesize about a possible mechanism.
GABA transmission plays a key role in controlling seizure activity in rats ~. Function and effect of GABA depends on the anatomic site of the GABA enhancement. There is a GABA-ergic pathway from substantia nigra (SN) pars reticularis to the tectum cells (the nigro-collicular pathway). In rats, activation of certain neurons in the tectum is anti-convulsant. When GABA is elevated and GABA-transmission is enhanced in the SN, the nigro-collicular GABA neurons are inhibited and consequently turn off the GABA that goes to the tectum. This results in a disinhibition (i.e. activation) of target cells in the tectum where the GABA-level increases (anticonvulsive effect). Conversely, if GABAtransmission in the nigro-collicular pathway were to increase, the opposite effect would be achieved, i.e. suppression of target ceils in the tectum to produce a proconvulsive condition. Therefore, while GABA elevation in the SN is anticonvulsive, GABA elevation in the nigrocollicular pathway is proconvulsive.
In the same way, a disinhibition of the principal excitatory neurons of the hippocampal formation due to increased inhibitory neurons in the hippocampus (as seen in seizure sensitive gerbils during GVG treatment) is postulated to result in focal seizure activity within the hippocampus and seizure generalization through multiple synaptic connections ~5.
GVG is a strong irreversible inhibitor of GABA-transaminase by which it increases the GABA level in the brain. Injury in the SN pars reticularis could result in a dysregulation of this mechanism, so GVG could have a proconvulsive effect instead of the intended anticonvulsant effect t.
After a certain time during SE, in rats cerebral damage in vulnerable areas is seen. The neurons in the SN pars reticularis are effected after 30 minutes of continuous SE despite control of blood pressure, ventilation and blood pH. After 45-60 minutes, damage occurs in the third and fourth cortex layer and specific areas of the hippocampus. In the SN this damage is probably the result of a huge energy deficiency and excessive lactate accumulation ~6"j7.
The three patients concerned all had refractory epilepsy and more or less severely damaged brains. In addition to her neurological handicap, the first patient went through two earlier SE. The second patient has been operated for a fibrosarcoma of the brain with subsequent radiotherapy. Moreover, in neurofibromatosis type 1, migrational disturbances are seen TM. The third patient has a severe mental handicap and refractory generalized epilepsy with daily seizures, both supposedly due to severe perinatal asphyxia.
We conclude that although SE. during GVG treatment could be a coincidence or due to changes in the current anti-epileptic drug treatment, this proconvulsive effect could also be explained by a disinhibition at the SN pars reticularis level, as described by this case report, or by disinhibition of excitatory neurons of the hippocampal formation.
A possible proconvulsive effect should be taken into account when GVG treatment is considered for brain-damaged patients, or when, during GVG treatment, reduction in the doses of the original anti-epileptic drugs is considered.
Further study of epileptic patients on GVG is required to find out the real nature of the effects reported in this paper.
